Shots:

• The approval is based on P-III study results assessing Seysar (sarecycline) in patients with inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older
• The study resulted in safe and effective results in P-III study in patients with moderate to server acne
• Seysara (sarecycline) is a qd- PO- narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne

Ref: Paratek | Image: Twitter